Journal of the American Chemical Society
Communication
(15) (a) Halperin, S. D.; Fan, H.; Chang, S.; Martin, R. E.; Britton, R.
Angew. Chem., Int. Ed. 2014, 53, 4690. (b) Halperin, S. D.; Kwon, D.;
Holmes, M.; Regalado, E. L.; Campeau, L.-C.; DiRocco, D. A.; Britton,
R. Org. Lett. 2015, 17, 5200. (c) Nodwell, M. B.; Bagai, A.; Halperin, S.
D.; Martin, R. E.; Knust, H.; Britton, R. Chem. Commun. 2015, 51,
11783.
(16) Renneke, R. F.; Pasquali, M.; Hill, C. L. J. Am. Chem. Soc. 1990,
112, 6585.
(17) Rueda-Becerril, M.; Sazepin, C. C.; Leung, J. C. T.; Okbinoglu,
T.; Kennepohl, P.; Paquin, J.-F.; Sammis, G. M. J. Am. Chem. Soc.
2012, 134, 4026.
Notes
The authors declare no competing financial interest.
ACKNOWLEDGMENTS
■
This work was supported by an NSERC Discovery Grant to
R.B., a MSFHR Career Investigator Award to R.B., a
Hoffmann-La Roche Fellowship (RPF) for M.B.N. and a
CCSRI Innovation Grant to P.S. The authors thank the
TRIUMF TR13 cyclotron team, in particular David Prevost,
Linda Graham and Samuel Varah. TRIUMF receives federal
funding via a contribution agreement with the National
Research Council of Canada. The authors also thank Nadine
Colpo at BC Cancer Research imaging facility for technical
support.
(18) Teare, H.; Robins, E. G.; Årstad, E.; Luthra, S. K.; Gouverneur,
V. Chem. Commun. 2007, 2330.
(19) (a) Buckingham, F.; Kirjavainen, A. K.; Forsback, S.;
Krzyczmonik, A.; Keller, T.; Newington, I. M.; Glaser, M.; Luthra, S.
K.; Solin, O.; Gouverneur, V. Angew. Chem., Int. Ed. 2015, 54, 13366.
(b) Buckingham, F.; Gouverneur, V. Chem. Sci. 2016, 7, 1645.
(c) Teare, H.; Robins, E. G.; Kirjavainen, A.; Forsback, S.; Sandford,
G.; Solin, O.; Luthra, S. K.; Gouverneur, V. Angew. Chem., Int. Ed.
2010, 49, 6821.
REFERENCES
■
(1) (a) Phelps, M. E. Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 9226.
(b) Ametamey, S. M.; Honer, M.; Schubiger, P. A. Chem. Rev. 2008,
108, 1501.
(20) For the synthesis of 4-[19F]FL, see: (a) Padmakshan, D.;
Bennett, S. A.; Otting, G.; Easton, C. J. Synlett 2007, 1083. (b) Truong,
V. L.; Gauthier, J. Y.; Boyd, M.; Roy, B.; Scheigetz, J. Synlett 2005,
1279.
of apparatuses, cell uptake, biodistribution and imaging data.
(2) Gambhir, S. S. Nat. Rev. Cancer 2002, 2, 683.
(3) Sharma, R.; Aboagye, E. Br. J. Pharmacol. 2011, 163, 1565.
(4) (a) Zhu, A.; Lee, D.; Shim, H. Semin. Oncol. 2011, 38, 55.
(b) Plathow, C.; Weber, W. A. J. Nucl. Med. 2008, 49, 43S.
(5) (a) Som, P.; Atkins, H. L.; Bandoypadhyay, D.; Fowler, J. S.;
MacGregor, R. R.; Matsui, K.; Oster, Z. H.; Sacker, D. F.; Shiue, C. Y.;
Turner, H.; Wan, C.-N.; Wolf, A. P.; Zabinski, S. V. J. Nucl. Med. 1980,
21, 670. (b) Kelloff, J.; Hoffman, J. M.; Johnson, B.; Scher, H. I.;
Siegel, B. A.; Cheng, E. Y.; Cheson, B. D.; O’shaughnessy, J.; Guyton,
K. Z.; Mankoff, D. A.; Shankar, L.; Larson, S. M.; Sigman, C. C.;
Schilsky, R. L.; Sullivan, D. C. Clin. Cancer. Res. 2005, 11, 2785.
(6) Langen, K.-J.; Hamacher, K.; Weckesser, M.; Floeth, F.; Stoffels,
G.; Bauer, D.; Coenen, H. H.; Pauleit, D. Nucl. Med. Biol. 2006, 33,
287.
(7) Qu, W.; Zha, Z.; Ploessl, K.; Lieberman, B. P.; Zhu, L.; Wise, D.
R.; Thompson, C. B.; Kung, H. F. J. Am. Chem. Soc. 2011, 133, 1122.
(8) (a) Huang, C.; McConathy, J. J. Nucl. Med. 2013, 54, 1007.
(b) Jager, P. L.; Vaalburg, W.; Pruim, J.; de Vries, E. G.; Langen, K. J.;
Piers, D. A. J. Nucl. Med. 2001, 42, 432. (c) Laverman, P.; Boerman, O.
C.; Corstens, F. H.; Oyen, W. J. Eur. J. Nucl. Med. Mol. Imaging 2002,
29, 681. (d) McConathy, J.; Goodman, M. M. Cancer Metastasis Rev.
2008, 27, 555.
(22) Demling, J.; Langer, K.; Worthmuller, M.; Yusufu, V. Amino
̈
̈
Acids 1993, 5, 253.
(23) The SA of [18F]NFSI, and consequently 7−10, can be increased
by lengthening the irradiation time of [18O]O2; a 5−10 min irradiation
was chosen to limit radioactive exposure. Additionally, high SA [18F]F2
(up to 55 GBq μmol−1) can be prepared using a process described in:
Bergman, J.; Solin, O. Nucl. Med. Biol. 1997, 24, 677.
(24) Bishop, A.; Satyamurthy, N.; Bida, G.; Phelps, M.; Barrio, J. R.
Nucl. Med. Biol. 1996, 23, 385.
(25) The SA of clinical doses of L-6-[18F]fluoro-DOPA (FDOPA)
are typically 4−8 MBq μmol−1. See: Turjanski, N.; Sawle, G. V.;
Playford, E. D.; Weeks, R.; Lammerstma, A. A.; Lees, A. J.; Brooks, D.
J. J. Neurol., Neurosurg. Psychiatry 1994, 57, 688.
(26) Barretina, J.; et al. Nature 2012, 483, 603.
(27) Kim, C. S.; Cho, S. H.; Chun, H. S.; Lee, S. Y.; Endou, H.;
Kanai, Y.; Kim, D. K. Biol. Pharm. Bull. 2008, 31, 1096.
(28) Limanto, J.; Shafiee, A.; Devine, P. N.; Upadhyay, V.; Desmond,
R. A.; Foster, B. R.; Gauthier, D. R.; Reamer, R. A.; Volante, R. P. J.
Org. Chem. 2005, 70, 2372.
(9) (a) Wang, Q.; Holst, J. Am. J. Cancer Res. 2015, 5, 1281.
(b) Fuchs, B. C.; Bode, B. P. Semin. Cancer Biol. 2005, 15, 254.
(c) Uchino, H.; Kanai, Y.; Kim, D. K.; Wempe, M. F.; Chairoungdua,
A.; Morimoto, E.; Anders, M. W.; Endou, H. Mol. Pharmacol. 2002, 61,
729.
(10) Saxton, R. A.; Knockenhauer, K. E.; Wolfson, R. L.;
Chantranupong, L.; Pacold, M. E.; Wang, T.; Schwartz, T. U.;
Sabatini, D. M. Science 2016, 351, 53.
(29) Galli, C.; Illuminati, G.; Mandolini, L.; Tamborra, P. J. Am.
Chem. Soc. 1977, 99, 2591.
(30) The fluorination of 1-aminocyclobutane carboxylic acid (a
potential precursor to FACBC), phenylalanine, tyrosine, histidine,
tryptophan and two Leu-containing dipeptides was also explored.
While the amino acids failed to fluorinate to any appreciable degree
(<5%), the dipeptides Phe-Leu (48%, 6 h) and Tyr-Leu (24%, 6 h)
fluorinated cleanly on the Leu residue, though the reaction time may
for full details).
(11) (a) Mu, F.; Mangner, T. J.; Chugani, H. T. J. Labelled Compd.
Radiopharm. 2005, 48, S189. (b) Alkonyi, B.; Chugani, H. T.; Muzik,
O.; Chugani, D. C.; Sundaram, S. K.; Kupsky, W. J.; Batista, C. E.;
Juhas
́
z, C. J. Neuroimaging 2012, 22, 177.
(31) Nagamori, S.; Wiriyasermkul, P.; Okuda, S.; Kojima, N.; Hari,
Y.; Kiyonaka, S.; Mori, Y.; Tominaga, H.; Ohgaki, R.; Kanai, Y. Amino
Acids 2016, 48, 1045.
(12) (a) Schuster, D. M.; Nanni, C.; Fanti, S.; Oka, S.; Okudaira, H.;
Inoue, Y.; Sorensen, J.; Owenius, R.; Choyke, P.; Turkbey, B.;
̈
Bogsrud, T. V.; Bach-Gansmo, T.; Halkar, R. K.; Nye, J. A.; Odewole,
O. A.; Savir-Baruch, B.; Goodman, M. M. J. Nucl. Med. 2014, 55, 1986.
(b) McConathy, J.; Voll, R. J.; Yu, W.; Crowe, R. J.; Goodman, M. M.
Appl. Radiat. Isot. 2003, 58, 657.
(13) Liu, Z.; Chen, H.; Chen, K.; Shao, Y.; Kiesewetter, D. O.; Niu,
G.; Chen, X. Sci. Adv. 2015, 1, e1500694.
(14) (a) For late-stage C-H [18F]-fluorination with [18F]F2, see:
Firnau, G.; Chirakal, R.; Garnett, E. S. J. Nucl. Med. 1984, 25, 1228.
(b) with [18F]CH3CO2F, see: Chirakal, R.; Firnau, G.; Couse, J.;
Garnett, E. S. Int. J. Appl. Radiat. Isot. 1984, 35, 651. (c) For benzylic
C-H 18F-fluorination, see: Huang, X.; Liu, W.; Ren, H.; Neelamegam,
R.; Hooker, J. M.; Groves, J. T. J. Am. Chem. Soc. 2014, 136, 6842.
D
J. Am. Chem. Soc. XXXX, XXX, XXX−XXX